Karachi: BF Biosciences Limited, a key player in the pharmaceutical sector, has released its financial statements for the fiscal year ending June 30, 2025, showcasing substantial growth in both revenue and profit compared to the previous year.

On September 23, 2025, the company disclosed that its net revenue surged to 5.84 billion rupees, a notable increase from the previous year's 3.66 billion rupees. This represents a very large or significant move, indicating robust performance in its market operations. The cost of goods sold stood at 3.55 billion rupees, leading to a gross profit of 2.29 billion rupees, up from 1.53 billion rupees in the prior year.

According to information available from the Pakistan Stock Exchange (PSX), BF Biosciences' equity and liabilities have also seen significant changes. The company's total equity and reserves climbed to 4.66 billion rupees from 2.36 billion rupees. Issued, subscribed, and paid-up capital increased to 265.00 million rupees. Furthermore, the share premium rose to 1.78 billion rupees, marking a new entry in the financial records compared to the previous year.

The balance sheet reflects a strategic shift in the company's financial management. Non-current liabilities decreased to 1.87 billion rupees from 2.07 billion rupees, while current liabilities rose slightly to 1.62 billion rupees from 1.43 billion rupees. The company's assets also expanded, with non-current assets valued at 4.32 billion rupees and current assets increasing to 3.84 billion rupees from 1.68 billion rupees.

The profit after taxation for the year amounted to 447.15 million rupees, demonstrating a moderate move from the previous year's 385.41 million rupees. This resulted in basic and diluted earnings per share of 5.52 rupees, a decline from 6.09 rupees in the prior year.

BF Biosciences' financial performance reflects its strategic efforts to enhance revenue streams while managing costs effectively. The company's growth trajectory is evident in the significant increases in both revenue and profit, as well as in its enhanced financial position within the industry.